Cited by 1,403Atrial Fibrillation Management and OutcomesClinical practice guidelines implementationAcute Ischemic Stroke Management

The DOI matches its Crossref record; 1,039 of the 1,039 references it cites were found in a registry or an index.

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Open access

Abstract

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) and by the European Association for Cardio-Thoracic Surgery (EACTS), as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. Members of this Task Force were selected by the ESC, including representation from the European Heart Rhythm Association (EHRA), and EACTS as well as by the European Stroke Organisation (ESO) to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) policy and approved by the EACTS and ESO. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 and 2.

Overview

Integrity signals

Registry

Crossref · 10.1093/ejcts/ezw313

Cites

1039 of 1039 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

2 retracted

Items 1,001–1,039 of 1,039

Flagged first, then by citations

Research works printed but not linked: 15

  1. Ponikowski, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J
  2. Nieuwlaat, 2007, Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation, The Euro Heart Survey on Atrial Fibrillation. Am Heart J, 153, 1006
  3. Kirchhof, 2007, Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA), Eur Heart J, 28, 2803, 10.1093/eurheartj/ehm358 · DOI
  4. Stroke Prevention in Atrial Fibrillation Investigators, 1991, Stroke Prevention in Atrial Fibrillation Study, Final results. Circulation, 84, 527
  5. Whitlock, 2014, Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III, Ann Cardiothorac Surg, 3, 45
  6. Segal, The evidence regarding the drugs used for ventricular rate control, In. J Fam Practice 2000;, 49, 47
  7. Waldo, 1996, Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators, Survival With Oral d-Sotalol. Lancet, 348, 7
  8. Savelieva, 2011, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines, Part II: secondary prevention. Europace, 13, 610
  9. Swedberg, 2012, Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study, J Am Coll Cardiol, 59, 1598, 10.1016/j.jacc.2011.11.063 · DOI · Paper page
  10. Cappato, 2014, Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation, Eur Heart J, 35, 3346, 10.1093/eurheartj/ehu367 · DOI
  11. Mohanty, Impact of Rotor Ablation in Non-Paroxysmal AF Patients: Results from a Randomized Trial (OASIS), J Am Coll Cardiol
  12. Wharton, 1998, Effect of pacing modality on atrial tachyarrhythmia recurrence in the tachycardia-bradycardia syndrome: preliminary results of the Pacemaker Atrial Tachycardia Trial, Circulation, 98
  13. Watanabe, 2008, Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans, J Clin Invest, 118, 2260
  14. Blomstrom-Lundqvist, 2003, ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society, J Am Coll Cardiol, 42, 1493
  15. Zheng, 2016, Perioperative Rosuvastatin in Cardiac Surgery, N Engl J Med, 374, 1744, 10.1056/NEJMoa1507750 · DOI · Paper page

Cited by

Sorted by citations

See all 1,403

Metadata

Authors
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Popescu, B. A., Schotten, U., Van Putte, B., Vardas, P., Agewall, S., Camm, J., Baron Esquivias, G., Budts, W., Carerj, S., Casselman, F., Coca, A., De Caterina, R., Deftereos, S., Dobrev, D., Ferro, J. M., Filippatos, G., Fitzsimons, D., Gorenek, B., Guenoun, M., Hohnloser, S. H., Kolh, P., Lip, G. Y. H., Manolis, A., McMurray, J., Ponikowski, P., Rosenhek, R., Ruschitzka, F., Savelieva, I., Sharma, S., Suwalski, P., Tamargo, J. L., Taylor, C. J., Van Gelder, I. C., Voors, A. A., Windecker, S., Zamorano, J. L., & Zeppenfeld, K.
Affiliations
University Hospitals Birmingham NHS Foundation Trust (GB)
Venue
European Journal of Cardio-Thoracic Surgery
Published
2016-09-23
Volume
50
Issue
5
Pages
e1-e88
ISSN
  • 1010-7940 (ISSN-L)
  • 1873-734X
OpenAlex
W2547585100
Cited by
1,403
References
1,039
Citations by year
2026: 16 · 2025: 26 · 2024: 88 · 2023: 98 · 2022: 125 · 2021: 181 · 2020: 246 · 2019: 209 · 2018: 227 · 2017: 161 · 2016: 22
FWCI
170.48
Type
journal article
Language
en
Open access
Locations
  • European Journal of Cardio-Thoracic Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • St George's Online Research Archive (St George's University of London) (acceptedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • BORIS (University Library Bern) (submittedVersion, other-oa)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • Lirias (submittedVersion)
  • ORBi (University of Liège) (submittedVersion, other-oa)
  • Research Portal (Queen's University Belfast) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Open Access CRIS of the University of Bern
Funders
  • National Institute for Health and Care Research (CL-2015-13-006, CDF-2015-08-074)
  • British Heart Foundation (RG/11/15/29375)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
atrial fibrillation, atrial fibrillation management, anticoagulation, stroke prevention, cardioversion, catheter ablation, rhythm control, atrial fibrillation diagnosis, risk-benefit assessment
MeSH terms
Anti-Arrhythmia Agents, Anticoagulants, Atrial Fibrillation, Electrocardiography, Hemorrhage, Humans, Mass Screening, Risk Factors, Sex Factors, Comorbidity, Incidence, Prevalence, Catheter Ablation, Evidence-Based Medicine, Disease Management, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review